Altered red cell and platelet adhesion in hemolytic diseases: Hereditary spherocytosis, paroxysmal nocturnal hemoglobinuria and sickle cell disease

Clinical Biochemistry

Volumn 46, Issue 18, 2013, Pages 1798-1803

  Sakamoto, Tatiana M ^a   Canalli, Andreia A ^a   Traina, Fabiola ^a,b   Franco Penteado, Carla F ^a   Gambero, Sheley ^a   Saad, Sara T O ^a   Conran, Nicola ^a   Costa, Fernando F ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Adhesion; Intravascular hemolysis; Platelets; Red cells

Indexed keywords

ALPHA4 INTEGRIN; CD36 ANTIGEN; CD59 ANTIGEN; CD71 ANTIGEN; DECAY ACCELERATING FACTOR; HEMOGLOBIN; LACTATE DEHYDROGENASE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; ERYTHROCYTE ADHESIVENESS; ERYTHROCYTE MEMBRANE; FEMALE; FLOW CYTOMETRY; HEMOGLOBIN BLOOD LEVEL; HEREDITARY SPHEROCYTOSIS; HUMAN; HUMAN CELL; INTRAVASCULAR HEMOLYSIS; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; MALE; MEAN CORPUSCULAR HEMOGLOBIN; MEAN CORPUSCULAR VOLUME; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETICULOCYTE; RETICULOCYTE COUNT; SICKLE CELL ANEMIA; SPLENECTOMY; THROMBOCYTE ADHESION; THROMBOCYTE COUNT;

ADHESION; INTRAVASCULAR HEMOLYSIS; PLATELETS; RED CELLS;

ADOLESCENT; ADULT; AGED; ANEMIA, SICKLE CELL; ANTIGENS, CD; ANTIGENS, CD36; BLOOD PLATELETS; CASE-CONTROL STUDIES; CHILD; ERYTHROCYTES; FEMALE; HEMOGLOBINURIA, PAROXYSMAL; HUMANS; INTEGRIN ALPHA4; L-LACTATE DEHYDROGENASE; MALE; MIDDLE AGED; PLATELET ADHESIVENESS; RECEPTORS, TRANSFERRIN; REFERENCE VALUES; RETICULOCYTE COUNT; SPHEROCYTOSIS, HEREDITARY; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84889654876     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2013.09.011     Document Type: Article

References (44)

1. Reiter C.D., Wang X., Tanus-Santos, Hogg N., Cannon R.O., Schechter A.N., et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med 2002, 8:1383-1389.
2. Mack A.K., Kato G.J. Sickle cell disease and nitric oxide: a paradigm shift?. Int J Biochem Cell Biol 2006, 38:1237-1243.
3. Rother R.P., Bell L., Hillmen P., Gladwin M.T. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA 2005, 293:1653-1662.
4. Schilling R.F., Gangnon R.E., Traver M.I. Delayed adverse vascular events after splenectomy in hereditary spherocytosis. J Thromb Haemost 2008, 6:1289-1295.
5. Canalli A.A., Conran N., Fattori A., Saad S.T., Costa F.F. Increased adhesive properties of eosinophils in sickle cell disease. Exp Hematol 2004, 32:728-734.
6. Canalli A.A., Franco-Penteado C.F., Traina F., Saad S.T., Costa F.F., Conran N. Role for cAMP-protein kinase a signalling in augmented neutrophil adhesion and chemotaxis in sickle cell disease. Eur J Haematol 2007, 79:330-337.
7. Gambero S., Canalli A.A., Traina F., Albuquerque D.M., Saad S.T., Costa F.F., et al. Therapy with hydroxyurea is associated with reduced adhesion molecule gene and protein expression in sickle red cells with a concomitant reduction in adhesive properties. Eur J Haematol 2007, 78:144-151.
8. Joneckis C.C., Ackley R.L., Orringer E.P., Wayner E.A., Parise L.V. Integrin alpha 4 beta 1 and glycoprotein IV (CD36) are expressed on circulating reticulocytes in sickle cell anemia. Blood 1993, 82:3545-3555.
9. Chiang E.Y., Frenette P.S. Sickle cell vaso-occlusion. Hematol Oncol Clin North Am 2005, 19:771-784.
10. Iolascon A., Avvisati R.A., Piscopo C. Hereditary spherocytosis. Transfus Clin Biol 2010, 17:138-142.
11. El Nemer W., Colin Y., Le Van Kim C. Role of Lu/BCAM glycoproteins in red cell diseases. Transfus Clin Biol 2010, 17:143-147.
12. Amer J., Zelig O., Fibach E. Oxidative status of red blood cells, neutrophils, and platelets in paroxysmal nocturnal hemoglobinuria. Exp Hematol 2007, 36:369-377.
13. Frei A.C., Gio Y., Jones D.W., Pritchard K.A., Fagan K.A., Hogg N., et al. Vascular dysfunction in a murine model of severe hemolysis. Blood 2008, 112:398-405.
14. Conran N., Gambero A., Ferreira H.H., Antunes E., de Nucci G. Nitric oxide has a role in regulating VLA-4-integrin expression on the human neutrophil cell surface. Biochem Pharmacol 2003, 66:43-50.
15. De Caterina R., Libby P., Peng H.B., Thannickal V.J., Rajavashisth T.B., Gimbrone M.A., et al. Nitric oxide decreases cytokines-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995, 96:60-68.
16. IIbbeta3-mediated platelet adhesion and outside-in signaling by nitric oxide. FEBS Lett 2007, 581:1529-1534.
17. Villagra J., Shiva S., Hunter L.A., Machado R.F., Gladwin M.T., Kato G.J. Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin. Blood 2007, 110:2166-2172.
18. Brodsky R.A. Advances in the diagnosis and therapy of paroxysmal nocturnal hemoglobinuria. Blood Rev 2008, 22:65-74.
19. Bellavite P., Andrioli G., Guzzo P., Arigliano P., Chirumbolo S., Manzato F., et al. A colorimetric method for the measurement of platelet adhesion in microtiter plates. Anal Biochem 1994, 216:444-450.
20. Stuart M.J., Nagel R.L. Sickle-cell disease. Lancet 2004, 364:1343-1360.
21. Dong H.Y., Wilkes S., Yang H. CD71 is selectively and ubiquitously expressed at high levels in erythroid precursors of all maturation stages: a comparative immunochemical study with glycophorin A and hemoglobin A. Am J Surg Pathol 2011, 35:723-732.
22. Telen M.J. Red blood cell surface adhesion molecules: their possible roles in normal human physiology and disease. Semin Hematol Apr 2000, 37(2):130-142.
23. Ninomiya H., Sato S., Hasegawa Y., Nagasawa T. Shortned lifespan of paroxysmal nocturnal haemoglobinuria-affected RBC estimated from differences in ratios of CD59-negative populations between reticulocytes and whole RBC. Int J Lab Hematol 2008, 30:41-45.
24. Neely C.L., Wajima T., Kraus A.P., Diggs L.W., Barreras L. Lactic acid dehydrogenase activity and plasma hemoglobin elevations in sickle cell disease. Am J Clin Pathol Aug 1969, 52(2):167-169.
25. Kato G.J., McGowan V., Machado R.F., Little J.A., Taylor J., Morris C.R., et al. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease 2006, 107(6):2279-2285.
26. Ballas S.K. Lactate dehydrogenase and hemolysis in sickle cell disease. Blood 2013, 121:243-244.
27. Kato G.J., Nouraie S.M., Gladwin M.T. Lactate dehydrogenase and hemolysis in sickle cell disease. Blood Aug 8 2013, 122(6):1091-1092.
28. Wimazal F., Sperr W.R., Kundi N., Vales A., Fonatsch C., Thalhammer-Scherrer R., et al. Prognostic significance of serial determinations of lactate dehydrogenase (LDH) in the follow-up of patients with myelodysplastic syndromes. Ann Oncol 2008, 19:970-976.
29. Akkerman J.W., Doucet-De Bruïne M.H., Gorter G., De Graaf S., Holme S., Lips J.P., et al. Evaluation of platelet tests for measurement of cell integrity. Thromb Haemost Feb 28 1978, 39(1):146-157.
30. Conran N., Ferreira H.H., Lorand-Metze I., Thomazzi S.M., Antunes E., de Nucci G. Nitric oxide regulates human eosinophil adhesion mechanisms in vitro by changing integrin expression and activity on the eosinophil cell surface. Br J Pharmacol 2001, 134:632-638.
31. Wills F.L., Gilchrist M., Befus A.D. Interferon-gamma regulates the interaction of RBL-2H3 cells with fibronectin through production of nitric oxide. Immunology 1999, 97:481-489.
32. Wandersee N.J., Olson S.C., Holzhauer S.L., Hoffman R.G., Barker J.E., Hillery C.A. Increased erythrocyte adhesion in mice and humans with hereditary spherocytosis and hereditary elliptocytosis. Blood 2004, 103:710-716.
33. Proença-Ferreira R., Franco-Penteado C.F., Traina F., Saad S.T.O., Costa F.F., Conran N. Increased adhesive properties of patients in sickle cell disease: roles for αIIbβ3-mediated ligand binding, diminished cAMP signaling and increased phosphodiesterase 3A activity. Br J Haematol 2009, 149:280-288.
34. Hill A., Kelly R.J., Hillmen P. Thrombosis in paroxysmal nocturnal hemoglobinuria. Blood 2013, 121:4985-4996.
35. Louwes H., Vellenga E., de Wolf J.T. Abnormal platelet adhesion on abdominal vessels in asymptomatic patients with paroxysmal nocturnal hemoglobinuria. Ann Hematol 2001, 80:573-576.
36. Schaer D.J., Buehler P.W., Alayash A.I., Belcher J.D., Vercellotti G.M. Hemolysis and free hemoglobin revisited: exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins. Blood 2013, 121:1276-1284.
37. Conran N., Franco-Penteado C.F., Costa F.F. Newer aspects of the pathophysiology of sickle cell disease vaso-occlusion. Hemoglobin 2009, 33:1-16.
38. Zelová H., Hošek J. TNF-α signalling and inflammation: interactions between old acquaintances. Inflamm Res 2013, 62:641-651.
39. Brodsky R.A. Narrative review: paroxysmal nocturnal hemoglobinuria: the physiology of complement-related hemolytic anemia. Ann Intern Med 2008, 148:587-595.
40. Gallagher P.G. Disorders of red blood cell membrane: hereditary spherocytosis, elliptocytosis and related disorders. Williams hematology 2006, 571-602. 7th ed. K.K. Lichtman MA KT, E. Beutler, U. Seligsohn, J.F. Prchal (Eds.).
41. Eber S., Lux S.E. Hereditary spherocytosis-defects in proteins that connect the membrane skeleton to the lipid bilayer. Semin Hematol 2004, 41:118-141.
42. Ataga K.I., Moore C.G., Hillery C.A., Jones S., Whinna H.C., Strayhorn D., et al. Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension. Haematologica 2008, 93:20-26.
43. Lanaro C., Franco-Penteado C.F., Albuqueque D.M., Saad S.T., Conran N., Costa F.F. Altered levels of cytokines and inflammatory mediators in plasma and leukocytes of sickle cell anemia patients and effects of hydroxyurea therapy. J Leukoc Biol 2009, 85:235-242.
44. Belcher J.D., Bryant C.J., Nguyen J., Bowlin P.R., Kielbik M.C., Bischof J.C., et al. Transgenic sickle mice have vascular inflammation. Blood 2003, 101:3953-3959.